

Commercial/Healthcare Exchange PA Criteria

Effective: February 6th, 2019

Prior Authorization: Lokelma

Products Affected: Lokelma (sodium zirconium cryosilicate for oral suspension)

Medication Description: Lokelma is a non-absorbed potassium-binding polymer. It acts by binding to potassium in the GI tract, increasing excretion of potassium in feces and lowers serum potassium levels.

Covered Uses: Treatment of hyperkalemia in adults

Exclusion Criteria: Emergency treatment for life-threatening hyperkalemia

Required Medical Information:

1. Diagnosis
2. Chart notes documenting previous therapies tried and failed.

Age Restrictions: 18 years of age or older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

Approve if the patient meets the following criteria:

Initial

- A. Patient has a diagnosis of hyperkalemia; **AND**
- B. Patient is not experiencing life-threatening hyperkalemia; **AND**
- C. Patient has inadequate response, intolerance or contraindication to Kayexalate (sodium Polystyrene sulfonate)

Continuation

- A. Patient has not experienced treatment-limiting adverse reactions (e.g. edema) **AND**
- B. There is documented efficacy (e.g. serum potassium levels within normal limits [3.5 to 5mEq/L]).

References:

1. Lokelma [package insert], Wilmington, DE; AstraZeneca; May 2018.
2. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. JAMA. 2014; 312(21): 2223-2233 DOI: 10.1001/jama.2014.15688.
3. Packham D, Rasmussen HS, Lavin P, et al. Sodium zirconium cyclosilicate in hyperkalemia. New Engl J Med. 2015; 372: 222-231. DOI: 10.1056/NEJMoa1411487.
4. Hyperkalemia. Available at: <http://emedicine.medscape.com/article/240903-overview>. Accessed January 22, 2019.
5. Available at: <http://clinicalpharmacology.com>. Accessed January 22, 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	01/02/2019

Last Res. January 2, 2019